ChemoCentryx, Inc. (CCXI) Analysts See $-0.28 EPS; Lookers plc (LON:LOOK) Had 2 Bulls

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

Among 2 analysts covering Lookers PLC (LON:LOOK), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Lookers PLC had 6 analyst reports since August 15, 2018 according to SRatingsIntel. Peel Hunt maintained the stock with “Buy” rating in Friday, August 24 report. The stock of Lookers plc (LON:LOOK) has “Buy” rating given on Tuesday, December 18 by Peel Hunt. The firm has “Buy” rating by Peel Hunt given on Wednesday, August 15. The firm has “Buy” rating by Peel Hunt given on Wednesday, November 7. The firm has “Buy” rating by Numis Securities given on Wednesday, August 15. The stock of Lookers plc (LON:LOOK) has “Buy” rating given on Friday, October 19 by Peel Hunt. See Lookers plc (LON:LOOK) latest ratings:

18/12/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 150.00 Maintain
07/11/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 150.00 Maintain
19/10/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 150.00 Maintain
24/08/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 150.00 Maintain
15/08/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 130.00 New Target: GBX 140.00 Maintain
15/08/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 150.00 Maintain

Analysts expect ChemoCentryx, Inc. (NASDAQ:CCXI) to report $-0.28 EPS on March, 8.They anticipate $1.08 EPS change or 135.00% from last quarter’s $0.8 EPS. After having $-0.22 EPS previously, ChemoCentryx, Inc.’s analysts see 27.27% EPS growth. The stock decreased 0.64% or $0.07 during the last trading session, reaching $11.68. About 58,972 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 69.59% since February 6, 2018 and is uptrending. It has outperformed by 69.59% the S&P500. Some Historical CCXI News: 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M

The stock decreased 0.19% or GBX 0.2 during the last trading session, reaching GBX 107.4. About 402,810 shares traded. Lookers plc (LON:LOOK) has 0.00% since February 6, 2018 and is . It has by 0.00% the S&P500.

More news for Lookers plc (LON:LOOK) were recently published by: Finance.Yahoo.com, which released: “Hays plc (LON:HAS) Earns A Nice Return On Capital Employed – Yahoo Sports” on January 24, 2019. Finance.Yahoo.com‘s article titled: “Should You Worry About MedaPhor Group plc’s (LON:MED) CEO Pay Cheque? – Yahoo Sports” and published on January 09, 2019 is yet another important article.

Lookers plc engages in the sale, hire, and maintenance of motor vehicles and motorcycles in the United Kingdom and Ireland. The company has market cap of 417.87 million GBP. The firm engages in the sale of new and used cars, and vans; and servicing, repair, and sale of franchised parts to customersÂ’ vehicles. It has a 8.73 P/E ratio. It operates 160 franchised dealerships representing 33 marques from 102 locations.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Seekingalpha.com which released: “ChemoCentryx withdraws conditional approval application for avacopan in Europe – Seeking Alpha” on January 24, 2019, also Seekingalpha.com with their article: “ChemoCentryx terminates previously announced common stock offering – Seeking Alpha” published on September 28, 2018, Globenewswire.com published: “ChemoCentryx Announces Proposed Public Offering of Common Stock – GlobeNewswire” on September 26, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Seekingalpha.com and their article: “ChemoCentryx launches $75M stock offering – Seeking Alpha” published on September 26, 2018 as well as Globenewswire.com‘s news article titled: “ChemoCentryx Reports Third Quarter 2018 Financial Results and Recent Highlights – GlobeNewswire” with publication date: November 08, 2018.

Investors sentiment decreased to 0.98 in 2018 Q3. Its down 0.61, from 1.59 in 2018Q2. It fall, as 14 investors sold ChemoCentryx, Inc. shares while 29 reduced holdings. 13 funds opened positions while 29 raised stakes. 26.80 million shares or 1.64% more from 26.37 million shares in 2018Q2 were reported. Adams Diversified Equity Fund Incorporated accumulated 0.03% or 40,200 shares. Amer International Group has 14,904 shares for 0% of their portfolio. Renaissance Technology Ltd invested in 0.01% or 772,281 shares. Landscape Cap Ltd Liability Corporation, New Jersey-based fund reported 10,285 shares. California State Teachers Retirement reported 34,380 shares. Invesco Ltd holds 136,127 shares. Swiss Bank has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Fosun Int Ltd, a Hong Kong-based fund reported 159,050 shares. State Of Wisconsin Investment Board reported 19,000 shares. Jacobs Levy Equity Management has 0.01% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 41,908 shares. Acadian Asset Limited Company invested in 896,380 shares. Clarivest Asset Mngmt Ltd Liability owns 53,100 shares. Vanguard Grp Inc Inc has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Rhumbline Advisers has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Bvf Il has 7.52% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 6.77M shares.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $589.89 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 47.27 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe Crohn’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

Since October 16, 2018, it had 0 insider buys, and 8 sales for $87.64 million activity. 30,237 shares valued at $332,779 were sold by Cappel Markus J. on Friday, October 26. On Thursday, January 10 Schall Thomas J. sold $447,092 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) or 36,762 shares. GLAXOSMITHKLINE PLC sold 7.34 million shares worth $85.85 million. KANAYA SUSAN M had sold 37,893 shares worth $457,747 on Tuesday, January 22.

Among 3 analysts covering ChemoCentryx (NASDAQ:CCXI), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. ChemoCentryx had 3 analyst reports since August 14, 2018 according to SRatingsIntel. The stock has “Buy” rating by Canaccord Genuity on Monday, November 12. JP Morgan downgraded ChemoCentryx, Inc. (NASDAQ:CCXI) on Tuesday, August 14 to “Neutral” rating.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *